. 12 Cavo M Tacchetti P Patriarca F . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly
Search Results
Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Philip L. McCarthy
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba
% CI, 31.5–not reached [NR]) in the midostaurin group compared with 25.6 months (95% CI, 18.6–42.9) in the placebo group ( P =.009). 32 Patients who received midostaurin with standard induction and consolidation therapy experienced significant
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective
Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, and Yiduo Zhang
, durvalumab remained cost-effective, with an ICER of $79,609 per QALY. Therefore, our analysis builds on the work of Criss et al 35 to provide a more robust estimate of the costs associated with durvalumab consolidation therapy, given current clinical
Therapeutic Advances in Relapsed or Refractory Multiple Myeloma
Kenneth C. Anderson
-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis . Haematologica 2011 ; 96 ( s1 ): S96 . Abstract P224 . 2
Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma
Scott M. Schuetze
the Children's Oncology Group . J Clin Oncol 2006 ; 24 : 152 – 159 . 56. Meyers PA Krailo MD Ladanyi M . High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high
Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?
Yvonne A. Efebera and Nina Shah
group and Dana-Farber Cancer Institute. 2 In this study, investigators randomly assigned patients with MM to receive either (1) induction therapy with 3 cycles of lenalidomide/bortezomib/dexamethasone (RVD) and then consolidation therapy with either 5
Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia
Martin Tallman
be given for secondary AML or AML with MRC. GO can be given to patients who are CD33-positive with 7+3 induction and consolidation therapy on days 1, 4, and 7 or as a single agent days 1 and 8. The 2018 NCCN Guidelines for AML state that after
National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non–Small Cell Lung Cancer
Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen
consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study . J Clin Oncol 2019 ; 37 : 1558 – 1565 . 17. Palma DA
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification
Presented by: Natalie S. Callander
- versus 3-drug induction regimen. 4 This trend seemed to correlate with the 4-year PFS rates (87.2% vs 70.0%, respectively). In the MASTER trial, MRD assessments guided the continuation or cessation of posttransplant consolidation therapy. 5 This
Updates in the Management of Neuroblastoma
Presented by: Rochelle Bagatell
primary tumor is radiated.” More remains to be learned about the risks and benefits of metastatic site radiation. Immunotherapy and Targeted Agents for High-Risk Disease Anti-GD2 Antibody Therapy “In post-consolidation therapy, the addition of
